CHESS Health Expands Use of Contingency Management Platform to Transform Hepatitis C Care
December 17, 2024 09:02 ET
|
CHESS Health
Rochester, New York, Dec. 17, 2024 (GLOBE NEWSWIRE) -- CHESS Health is excited to announce an expanded use of its innovative digital Rewards Engine, a flexible automated contingency management tool...
bioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in Australia
May 19, 2024 18:00 ET
|
bioLytical Laboratories Inc.
bioLytical launches the INSTI® HCV Antibody Test in Australia with its inclusion on the Australian Register of Therapeutic Goods (ARTG number: 448926)
Hepatitis C Drug Market To Reach USD 26.9 Billion By 2032 Report By DataHorizzon Research
February 02, 2024 06:40 ET
|
DataHorizzon Research
Fort Collins, Colorado, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The Hepatitis C Drug Market was valued at USD 20.8 Billion in 2022 and is anticipated to reach USD 26.9 Billion by 2032 at a CAGR of 2.7%. ...
Hepatitis C Drug Market Size & Share to Surpass $56.5 Billion by 2030 | Vantage Market Research
August 17, 2023 05:30 ET
|
Vantage Market Research
WASHINGTON, Aug. 17, 2023 (GLOBE NEWSWIRE) -- According to Vantage Market Research, the Global Hepatitis C Drug Market is estimated to be valued at USD 56.5 Billion by 2030 and is expected to...
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
July 20, 2023 12:00 ET
|
CDA Foundation
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq:...
HepVu and NASTAD Release Inaugural Viral Hepatitis Surveillance Status Report
October 25, 2022 10:32 ET
|
HepVu
ATLANTA, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Today, HepVu and NASTAD released the first-ever assessment of viral hepatitis surveillance practices across U.S. jurisdictions, showing that while public...
Global Liver Fibrosis Treatment Market to Surpass US$ 33.4 Billion by 2030, Says Coherent Market Insights (CMI)
August 08, 2022 09:10 ET
|
CMI
Seattle, Aug. 08, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global liver fibrosis treatment market is estimated to be valued at US$ 14.7 billion in 2022 and is expected to...
HepVu Launches County-Level Hepatitis C-Related Mortality Data and Maps Visualizing Hepatitis C’s Impact on Americans at the Local-Level
March 03, 2021 12:44 ET
|
HepVu
ATLANTA, March 03, 2021 (GLOBE NEWSWIRE) -- Today, HepVu released new interactive maps visualizing U.S. county-level Hepatitis C-related mortality, illustrating how factors such as age and...
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 02, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Inc.’s Structure-Based Technology has Demonstrated Broad Utility in Development of Antivirals
February 13, 2020 08:30 ET
|
Cocrystal Pharma, Inc.
– Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address additional viral diseases,...